Comparison of Elisa-based tyrosine kinase assays for screening EGFR inhibitors

Edit Varkondi, Eszter Schäfer, Györgyi Bökönyi, Tibor Gyökeres, L. Őrfi, I. Peták, A. Pap, Orsolya Szokoloczi, G. Kéri, Richard Schwab

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Receptor tyrosine kinases (PTKs) play key roles in the pathogenesis of numerous human diseases, including cancer, and therefore PTK inhibitors are currently under intense investigation as potential drug candidates. PTK inhibitor screening data are, however, poorly comparable because of the different assay technologies used. Here we report a comparison of ELISA-based assays for screening epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitory compound libraries to study interassay variations. All assays were based on the same protocol, except for the source of EGFR-TK enzymes. In the first protocol, the enzyme was isolated from A431 cells without affinity purification. In the second protocol, commercial EGFR-TK (Sigma) isolated from A431 cells by affinity-purification was employed. In the third protocol, an enzyme preparation obtained from a recombinant (Baculovirus transfected Sf9 cells) expression system was used. All assays employed the synthetic peptide substrate poly-(Glu,Tyr)1:4 and an ELISA-based system to detect phosphorylated tyrosine residues by a monoclonal antibody. We observed significant differences in both the activity of the enzymes and in the EGFR-TK inhibitory effect of our reference compound PD153035. The differences were significant in case of A431 cell lysate compared to affinity purified EGFR-TKs derived from either A431 cells or Baculovirus transfected Sf9 cells, whereas the latter two showed comparable results. Our data suggest that differences in terms of interassay variation are not related to the source of the enzyme but to its purity; changes in the mode of detection can markedly influence the reproducibility of results. In conclusion, normalization of the EGFR activity used for inhibitor screening and standardization of detection methods enable safe comparison of data.

Original languageEnglish
Pages (from-to)45-56
Number of pages12
JournalJournal of Receptors and Signal Transduction
Volume25
Issue number1
DOIs
Publication statusPublished - 2005

Fingerprint

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Assays
Screening
Enzymes
Sf9 Cells
Baculoviridae
Purification
Enzyme-Linked Immunosorbent Assay
Receptor Protein-Tyrosine Kinases
Reproducibility of Results
Standardization
Libraries
Tyrosine
Monoclonal Antibodies
Technology
Peptides
Substrates
Pharmaceutical Preparations
Neoplasms

Keywords

  • ELISA
  • Epidermal growth factor receptor (EGFR)
  • Kinase inhibitor
  • Protein tyrosine kinase (PTK)
  • Screening

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Comparison of Elisa-based tyrosine kinase assays for screening EGFR inhibitors. / Varkondi, Edit; Schäfer, Eszter; Bökönyi, Györgyi; Gyökeres, Tibor; Őrfi, L.; Peták, I.; Pap, A.; Szokoloczi, Orsolya; Kéri, G.; Schwab, Richard.

In: Journal of Receptors and Signal Transduction, Vol. 25, No. 1, 2005, p. 45-56.

Research output: Contribution to journalArticle

Varkondi, Edit ; Schäfer, Eszter ; Bökönyi, Györgyi ; Gyökeres, Tibor ; Őrfi, L. ; Peták, I. ; Pap, A. ; Szokoloczi, Orsolya ; Kéri, G. ; Schwab, Richard. / Comparison of Elisa-based tyrosine kinase assays for screening EGFR inhibitors. In: Journal of Receptors and Signal Transduction. 2005 ; Vol. 25, No. 1. pp. 45-56.
@article{bbbe8452c4944d6abf7b3b8ed4a50883,
title = "Comparison of Elisa-based tyrosine kinase assays for screening EGFR inhibitors",
abstract = "Receptor tyrosine kinases (PTKs) play key roles in the pathogenesis of numerous human diseases, including cancer, and therefore PTK inhibitors are currently under intense investigation as potential drug candidates. PTK inhibitor screening data are, however, poorly comparable because of the different assay technologies used. Here we report a comparison of ELISA-based assays for screening epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitory compound libraries to study interassay variations. All assays were based on the same protocol, except for the source of EGFR-TK enzymes. In the first protocol, the enzyme was isolated from A431 cells without affinity purification. In the second protocol, commercial EGFR-TK (Sigma) isolated from A431 cells by affinity-purification was employed. In the third protocol, an enzyme preparation obtained from a recombinant (Baculovirus transfected Sf9 cells) expression system was used. All assays employed the synthetic peptide substrate poly-(Glu,Tyr)1:4 and an ELISA-based system to detect phosphorylated tyrosine residues by a monoclonal antibody. We observed significant differences in both the activity of the enzymes and in the EGFR-TK inhibitory effect of our reference compound PD153035. The differences were significant in case of A431 cell lysate compared to affinity purified EGFR-TKs derived from either A431 cells or Baculovirus transfected Sf9 cells, whereas the latter two showed comparable results. Our data suggest that differences in terms of interassay variation are not related to the source of the enzyme but to its purity; changes in the mode of detection can markedly influence the reproducibility of results. In conclusion, normalization of the EGFR activity used for inhibitor screening and standardization of detection methods enable safe comparison of data.",
keywords = "ELISA, Epidermal growth factor receptor (EGFR), Kinase inhibitor, Protein tyrosine kinase (PTK), Screening",
author = "Edit Varkondi and Eszter Sch{\"a}fer and Gy{\"o}rgyi B{\"o}k{\"o}nyi and Tibor Gy{\"o}keres and L. Őrfi and I. Pet{\'a}k and A. Pap and Orsolya Szokoloczi and G. K{\'e}ri and Richard Schwab",
year = "2005",
doi = "10.1081/RRS-200055095",
language = "English",
volume = "25",
pages = "45--56",
journal = "Journal of Receptor and Signal Transduction Research",
issn = "1079-9893",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Comparison of Elisa-based tyrosine kinase assays for screening EGFR inhibitors

AU - Varkondi, Edit

AU - Schäfer, Eszter

AU - Bökönyi, Györgyi

AU - Gyökeres, Tibor

AU - Őrfi, L.

AU - Peták, I.

AU - Pap, A.

AU - Szokoloczi, Orsolya

AU - Kéri, G.

AU - Schwab, Richard

PY - 2005

Y1 - 2005

N2 - Receptor tyrosine kinases (PTKs) play key roles in the pathogenesis of numerous human diseases, including cancer, and therefore PTK inhibitors are currently under intense investigation as potential drug candidates. PTK inhibitor screening data are, however, poorly comparable because of the different assay technologies used. Here we report a comparison of ELISA-based assays for screening epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitory compound libraries to study interassay variations. All assays were based on the same protocol, except for the source of EGFR-TK enzymes. In the first protocol, the enzyme was isolated from A431 cells without affinity purification. In the second protocol, commercial EGFR-TK (Sigma) isolated from A431 cells by affinity-purification was employed. In the third protocol, an enzyme preparation obtained from a recombinant (Baculovirus transfected Sf9 cells) expression system was used. All assays employed the synthetic peptide substrate poly-(Glu,Tyr)1:4 and an ELISA-based system to detect phosphorylated tyrosine residues by a monoclonal antibody. We observed significant differences in both the activity of the enzymes and in the EGFR-TK inhibitory effect of our reference compound PD153035. The differences were significant in case of A431 cell lysate compared to affinity purified EGFR-TKs derived from either A431 cells or Baculovirus transfected Sf9 cells, whereas the latter two showed comparable results. Our data suggest that differences in terms of interassay variation are not related to the source of the enzyme but to its purity; changes in the mode of detection can markedly influence the reproducibility of results. In conclusion, normalization of the EGFR activity used for inhibitor screening and standardization of detection methods enable safe comparison of data.

AB - Receptor tyrosine kinases (PTKs) play key roles in the pathogenesis of numerous human diseases, including cancer, and therefore PTK inhibitors are currently under intense investigation as potential drug candidates. PTK inhibitor screening data are, however, poorly comparable because of the different assay technologies used. Here we report a comparison of ELISA-based assays for screening epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitory compound libraries to study interassay variations. All assays were based on the same protocol, except for the source of EGFR-TK enzymes. In the first protocol, the enzyme was isolated from A431 cells without affinity purification. In the second protocol, commercial EGFR-TK (Sigma) isolated from A431 cells by affinity-purification was employed. In the third protocol, an enzyme preparation obtained from a recombinant (Baculovirus transfected Sf9 cells) expression system was used. All assays employed the synthetic peptide substrate poly-(Glu,Tyr)1:4 and an ELISA-based system to detect phosphorylated tyrosine residues by a monoclonal antibody. We observed significant differences in both the activity of the enzymes and in the EGFR-TK inhibitory effect of our reference compound PD153035. The differences were significant in case of A431 cell lysate compared to affinity purified EGFR-TKs derived from either A431 cells or Baculovirus transfected Sf9 cells, whereas the latter two showed comparable results. Our data suggest that differences in terms of interassay variation are not related to the source of the enzyme but to its purity; changes in the mode of detection can markedly influence the reproducibility of results. In conclusion, normalization of the EGFR activity used for inhibitor screening and standardization of detection methods enable safe comparison of data.

KW - ELISA

KW - Epidermal growth factor receptor (EGFR)

KW - Kinase inhibitor

KW - Protein tyrosine kinase (PTK)

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=20344407075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20344407075&partnerID=8YFLogxK

U2 - 10.1081/RRS-200055095

DO - 10.1081/RRS-200055095

M3 - Article

VL - 25

SP - 45

EP - 56

JO - Journal of Receptor and Signal Transduction Research

JF - Journal of Receptor and Signal Transduction Research

SN - 1079-9893

IS - 1

ER -